// App-Quantinova.ai

P204 : Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs

Researchers

Presenter

  • Bruce Kirkham

Principal Investigators

  • Elena Nikiphorou

  • Pedro Lpez-Romero

  • Ilias Kouris

  • Thorsten Holzkaemper

  • Liliana Zaremba-Pechmann

  • Inmaculada de la Torre

  • Peter C Taylor

Medical Centers

  • Centre for Rheumatic Diseases Department of Inflammation, Biology King’s College London, London, UNITED KINGDOM

  • Eli Lilly and Company, Indianapolis, IN

  • HaaPACS GmbH, HaaPACS GmbH, Schriesheim, GERMANY

  • Botnar Research Centre, University of Oxford, Oxford

Locations

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

  • Malondialdehyde

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved